View cart  |
 Cart is empty 
Order history   
Free Shipping on Canadian Orders Over $50

The Science Behind Estrosoy

The Science Behind EstroSoy

In today’s fast-paced environment, many people seek to supplement their diets with protein in order to reach optimum health and nutrition levels. EstroSoy Soy Protein Beverage Mix, a delicious and convenient source of soy protein, is just the supplement that you need.

EstroSoy Soy Protein provides all the health and nutritive benefits of a protein supplement in a vegetarian, cholesterol-free, dairy-free format. It contains no added sugar, is suitable for use as part of a high protein diet, and consists of only water-processed Supro® brand soy protein isolate - the world leader in quality soy protein.

Supplementation with soy protein has been shown in scientific studies to safely help lower cholesterol levels and the risk of cardiovascular disease, inhibit the growth of cancer cells, help decrease the risk of osteoporosis, and to be an effective treatment to reduce and prevent the symptoms of menopause. EstroSoy increases the value of soy protein as a supplement with the addition of the enzymes bromelain and papain, both of which enhance the digestibility and bioavailability of the protein.

Soy Protein

Soy is an ideal source of high quality protein. Not only is the protein excellent quality, but it is also 100% vegetarian and 100% dairy-free. Furthermore, soy protein has unique qualities that make it a prime choice for your protein needs.

Soy protein contains molecules known as isoflavone phytoestrogens. Isoflavones are phenolic estrogens and, when soy protein is included in the diet, these molecules are able to act like steroidal estrogen in the human body. The two main isoflavones found in soy protein are genistein and daidzein.

Scientific studies have indicated that eating soy protein, specifically the isoflavonic phytoestrogens it contains, is beneficial in reducing the risk of cardiovascular disease, osteoporosis, cancer, and menopause.

Cardiovascular Disease

The decline in estrogen levels experienced during and after menopause is linked to an increased risk of cardiovascular disease (CVD). CVD occurs as blood vessels are choked off by a build-up of plaque, preventing blood flow. The loss of blood flow results in a lack of oxygen, thereby damaging and killing the cells in the affected area. This can cause a heart attack or stroke.

Because plaques are made primarily of cholesterol, and because high cholesterol levels are linked with increased risk of CVD, efforts to reduce the risk of CVD have focused on decreasing the level of total plasma cholesterol. The most common way prescribed to prevent and treat CVD has been through lifestyle changes, including changes in diet. This is where soy protein comes in.

The effects of soy protein on risk factors of CVD have been under investigation for years. Researchers have found that replacing some of the animal protein in the diet with soy protein reduces the risk factors associated with CVD. A recently published meta-analysis (a powerful statistical tool used by scientists to pool all the results from many individual studies) described the effects of soy on blood lipid profiles. This study, which used the results from 38 controlled clinical trials, found that replacing part of the normal dietary animal protein with soy protein reduced the total cholesterol level by 9.3%, reduced low-density lipoprotein (LDL) or "bad cholesterol" by 12.9%, and increased high-density lipoprotein (HDL) or "good cholesterol" by 2.4%. The study also found that results were most profound for those people most at risk (those with the highest initial levels of total and LDL cholesterol). Benefits were obtained regardless of the level of fat intake in the diet. Although the scientific community is skeptical by nature, this meta-analysis has provided such rigorous proof of the benefit of soy protein that it is now widely accepted that soy provides benefits for human health.

More recent research has indicated that phytoestrogens are the bioactive component that affects cholesterol profiles in the blood. Increasing the intake of isoflavones will result in the increased secretion of cholesterol in bile acids. By this route, LDL cholesterol is eliminated from the blood stream. The absorption of cholesterol into the blood stream from the gastrointestinal tract is also inhibited by isoflavones. By lowering the levels of total and LDL cholesterol in the blood, isoflavones decrease the risk of plaque formation in blood vessels, thereby greatly diminishing the risk of a major cardiovascular event such as a heart attack or stroke.

The isoflavones genistein and daidzein also possess anti-oxidant properties that prevent the harmful oxidation of LDL cholesterol. The importance of these isoflavone actions is put into perspective when one considers that CVD is responsible for 40% of deaths in North America.


The isoflavones genistein and daidzein both have anti-cancer properties as evidenced by their ability to inhibit growth of cancer cells from the breast, prostate, colon and skin. In Japan, where soy is a major dietary constituent, the breast cancer mortality rate is one quarter of that in the United States. The US incidence of clinical prostate cancer is 10-15 times higher than the Japanese rate.

There appear to be a number of mechanisms by which the isoflavones inhibit cancer. Genistein is a specific inhibitor of several important enzymes and arrests cell growth by interfering with signal transduction pathways inside the cells. Additionally, phytoestrogens exhibit many other activities, and they inhibit the actions of cytokines and growth factors, all of which may contribute to the effectiveness of isoflavones as potential anti-cancer agents. <

As cancer is a major cause of mortality in North America, increasing the levels of isoflavones may be an important means of combating this disease.


The reduction in estrogen levels during and after menopause is also link with increased risk for osteoporosis and lower bone mineral density. Osteoporosis is the most common type of metabolic bone disease in the North America. It occurs when the body fails to form enough new bone or when too much of the old bone is reabsorbed by the body, or both. Usually, the loss occurs gradually over an extended period of time (years) and most of the time, a person will sustain a fracture before becoming aware that the disease is present. By the time this occurs, the disease is in its advanced stages and damage is profound.

There are a number of causes of osteoporosis, with hormone deficiencies such as decreased estrogen levels in women being the leading cause. Although bones are often thought of as being static, inactive tissue, this is not the case. Bone is constantly being remodeled. Old bone is absorbed by cells known as osteoclasts, and new bone is always being formed by cells known as osteoblasts. Theses two processes are in balance in healthy bones. When more bone is absorbed than is being produced, the bone becomes porous and weak, as occurs in osteoporosis. Estrogen is known to play a critical role in maintaining the balance between old bone absorption and new bone formation. When the level of estrogen drops, as occurs during menopause, the balance is thrown off. Because isoflavones mimic the action of estrogen, supplementation with soy can help ameliorate the loss of bone density associated with a decline in hormone levels.


It is estimated that approximately 85% of menopausal and post-menopausal women suffer from symptoms such as hot flashes, night sweats, irregular menses, and vaginal dryness, all due to changing estrogen levels. Although hormone replacement therapy (HRT) is an option, only 8-17% of these women accept HRT for relief of menopausal symptoms. It seems the risks associated with HRT treatment are too great for the majority of women.

Because of this, more and more women are turning to soy protein. Studies have shown that supplementation with soy protein can be used to treat the effects of menopause without the side effects associated with HRT.

One study, for example, showed up to 45% reduction in hot flashes in patients taking soy protein supplements. Clinical studies have also shown that soy protein and its constituent phytoestrogens can reduce the severity and frequency of other menopausal symptoms such as mood swings, night sweats, and vaginal dryness. The estrogenic effects of phytoestrogens are also linked to moderation of headaches, sex drive, weight changes, and irregular menses.

Bromelain and Papain

Since there is extensive metabolism in the intestines before absorption, the absorption of isoflavones depends on a healthy gut. This is why EstroSoy contains protein digesting enzymes such as bromelain and papain. These enzymes maximize the absorption of nutrients from the digestive tract.


All of the ingredients in EstroSoy are natural and safe. Soy products have been enjoyed for thousands of years without any safety concerns.

Some people may experience some intestinal discomfort if the dose of soy protein is too high. If this happens to you, cut your dosage back until symptoms disappear. Remember, more is not necessarily better. Follow recommended dosage guidelines for the best results.

This product is not for use by pregnant or breastfeeding women. Consult a physician prior to use if you use prescription medication or if you receive hormone replacements.

  • Adlercreutz, H and Mazur, W. 1997. Phyto-oestrogens and western disease. Ann Med 29:95-120.
  • Albertazzi, P, Pansini, F, Bonaccorsi, G, Zanotti, L, Forini, E, and De Aloysio, D. 1998. Obstet Gynecol 91:6-11.
  • Anderson, JJB, Ambrose, WW, and Garner, SC. 1998. Biphasic effects of genistein on bone tissue in the ovariectomized, lactating rat model. Proc Soc Exp Biol Med 217:345-350.
  • Anderson, JW, Johnstone, BM, and Cook-Newell, ME. 1995. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 333:276-282.
  • Anthony MS, Clarkson TB, Hughes CL Jr, Morgan TM, Burke GL. 1996. Soybean isoflavones improve cardiovascular risk factors without affecting the reproductive system of prepubertal rhesus monkeys. J Nutr 126:43-50.
  • Arjmandi, BH, Alekel, L, Hollis, BW, Amin, D, Stacewicz-Sapuntzakis, M, Guo, P, and Kukreja, SC. 1996. Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis. J Nutr 126:161-167.
  • Arjmundi, BH, Getlinger, MJ, Goyal, NV, Alekel, L, Hasler, CM, Juma, S, Drum, ML, Hollis, BW, and Kukreja, SC. 1998. Role of soy protein with normal or reduced isoflavone content in reversing bone loss induced by ovarian hormone deficiency in rats. Am J Clin Nutr 68 (Suppl):1358S-1363S.
  • Bakhit, RM, Klein, BP, Essex-Sorlie, D, Ham, JO, Erdman, JW, and Potter, SM. 1994. Intake of 25g of soybean protein with or without soybean fiber alters plasma lipids in men with elevated cholesterol concentrations. J Nutr 124:213-222.
  • Barnes, S. 1997. The chemoprotective properties of soy isoflavonoids in animal models of breast cancer. Breast Cancer Res Treat 46:169-179.
  • Barnes, S. 1998. Evolution of the health benefits of soy isoflavones. Proc Soc Exp Biol Med 217:386-392.
  • Baum J, Teng HY, Erdman JW Jr, et al. Long-term intake of soy protein lowers the risk of cardiovascular disease and increases mononuclear cell LDL receptor mRNA in hypercholesterolemic postmenopausal women. Am J Clin Nutr
  • Benson JR, Colleta AA. 1995. Transforming growth factor b . Prospects for cancer prevention and treatment. Clin Immunother 4:249-258.
  • Benson JR, Baum M, Colletta AA. 1996. Role of TGFb in the anti-estrogen response/resistance of human breast cancer. J Mammary Gland Biol Neoplasia 1:381-389.
  • Blair H, Jordan SE, Petersen TG, Barnes S. 1996. Variable effects of tyrosine kinase inhibitors on avian osteoclastic activity and reduction of bone loss in ovariectomized rats. J Cell Biochem 61:629-637.
  • Brandi, ML. 1992. Flavonoids: Biochemical effects and therapeutic applications. Bone Mineral 19 (Suppl):S3-S14.
  • Burke, GL. 1996. The potential use of a dietary soy supplement as a post-menopausal hormone replacement therapy. Second International Symposium on the role of Soy in Preventing and Treating Chronic Disease, September 15-18, 1996.
  • Clark JW, Santos-Moore A, Stevenson LE, Frackelton AR. 1996. Effects of tyrosine kinase inhibitors on the proliferation of human breast cancer lines and proteins important in the RAS signalling pathway. Int J Cancer 27:186-191.
  • Clarkson, TB, Anthony, MS, Williams, JK, Honore, EK, and Cline, JM. 1998. The potential of soybean phytoestrogens for postmenopausal hormone replacement therapy. Proc Soc Exp Biol Med 217:365-368.
  • Dalais FS, Rice GE, Bell RJ, et al. 1998. Dietary soy supplementation increases vaginal cytology maturation index and bone mineral content in postmenopausal women. Am J Clin Nutr 68(suppl):1518S.
  • Eden, J, Knight, D, Mackey, R, and House, FR. 1996. The hormonal effect of isoflavones. Second International Symposium on the role of Soy in Preventing and Treating Chronic Disease, September 15-18, 1996.
  • Fanti O, Faugere MC, Gang Z, Schmidt J, Cohen D, malluche HH. 1998. Systemic administration of genistein partially prevents bone loss in ovariectomized rats in a nonestrogen-like mechanism. Am J Clin Nutr 68(suppl)1517S.
  • Gyorgy P, Murata K, Ikehata H. 1964. Antioxidants isolated from fermented soybeans (tempeh). Nature 203:870-872.
  • Harding, C, Morton, M, Gould, V, McMichael Philips, D, Howell, A, and Bundred, NJ. 1996. Dietary soy supplementation is oestrogenic in menopausal women. Second International Symposium on the role of Soy in Preventing and Treating Chronic Disease, September 15-18, 1996.
  • Honore EK, Williams JK, Anthony MS, Clarkson TB. 1997. Soy isoflavones enhance coronary vascular reactivity in atherosclerotic female macaques. Fertil Steril 67:148-154.
  • Horn-Ross PL. 1995. Phytoestrogens, body composition, and breast cancer. Cancer Causes Control 6:567-573.
  • Jha HC, Von Recklinghausen G, Zilliken F. 1985. Inhibition of in vitro microsomal lipid peroxidation by isoflavonoids. Biochem Pharmacol 34:1367-1369.
  • Kim H, Peterson TG, Barnes S. 1998. Mechanisms of action of the soy isoflavone genistein: emerging role for its effects via transforming growth factor b signaling pathways. Am J Clin Nutr 68(suppl):1418S-25S.
  • Knight, DC and Eden, JA. 1996. A review of the clinical effects of phytoestrogens. Obstet Gynecol 87:897-904.
  • Kyle E, Neckers L, Takimoto C, Curt G, Bergan R. 1997. Genistein induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Mol Pharmacol 51:193-200.
  • Lamartiniere, CA, Murrill, WB, Manzolillo, PA, Zhang, JX, Barnes, S, Zhang, X, Wei, H, and Brown, NM. 1998. Genistein alters the ontogeny of mammary gland development and protects against chemically-induced mammary cancer in rats. Proc Soc Exp Biol Med 217:358-364.
  • Lamartiniere, CA, Zhang, JX, and Cotroneo, MS. 1998. Genistein studies in rats: potential for breast cancer prevention and reproductive and developmental toxicity. Am J Clin Nutr 68 (6 Suppl):1400S-1405S.
  • Lee HP, Gourly L, Duffy SW. 1991. Dietary effects on breast cancer risk in Singapore. Lancet 337:1197-1200.
  • Lichtenstein AH. 1998. Soy protein, isoflavones and cardiovascular disease risk. J Nutr 128:1589-1592.
  • Lock M. 1991. Contested meanings of the menopause. Lancet 337:1270-1272.
  • Markovits J, Linassier C, Fosse P, et al. 1989. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res 49:5111-5117.
  • Markowitz SD, Roberts AB. 1997. Tumor suppressor activity of the TGFb pathway in human cancers. Cytokine Growth Factor Rev 7:93-102.
  • McMichael-Philiips, DF, Harding, C, Morton, M, Roberts, SA, Howell, A, Potten, CS, and Bundred, NJ. 1998. Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast. Am J Clin Nutr 68 (6 Suppl):1431S-1435S.
  • Messina MJ. 1999. Legumes and soybeans: overview of their nutritional profiles and health effects. Am J Clin Nutr 70(suppl):439S-50S.
  • Messina M, Persky V, Setchell KDR, Barnes S. 1994. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 21:113-131.
  • Murkies AL, Lombard C, Strauss BJG, Wilcox G, Burger HG, Morton MS. 1995. Dietary flour supplementation decreases post-menopausal hot flushes: effect of soy and wheat. Maturitas 21:189-195.
  • Naik HR, Lehr JE, Pienta KJ. 1994. An in vitro and in vivo study of anti-tumor effects of genistein on hormone refractory prostate cancer. Anticancer Res 14:2617-2620.
  • Oddens, BJ. 1994. The climacteric cross-culturally: The International Health Foundation South-East Asia study. Maturitas 19:155-156.
  • Okura A, Arakawa H, Oka H, Yoshinari T, Monden Y. 1988. Effect of genistein on topoisomerase activity and on the growth of [val 12]Ha-ras-transformed NIH 3T3 cells. Biochem Biophys Res Commun 157:183-189.
  • Pagliacci MC, Smacchia M, Migliorati G, Grignana F, Riccardi C, Nicoletti I. 1994. Growth-inhibitory effects of the natural phytoestrogen genistein in MCF-7 human breast cancer cells. Eur J Cancer 30A:1675-1682.
  • Peterson G, Barnes S. 1991. Genistein inhibition of the growth of human breast cancer cells: independence from estrogen receptors and the multi-drug resistance gene. Biochem Biophys Res Commun 179:661-667.
  • Peterson G, Barnes S. 1993. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor autophosphorylation. Prostate 22:335-345.
  • Peterson G, Barnes S. 1996. Genistein inhibits both estrogen and growth factor stimulated proliferation of human breast cancer cells. Cell Growth Differ 7:1345-1351.
  • Peterson G, Coward L, Kirk M, Falany C, Barnes S.1996. The role of metabolism in mammary epithelial growth inhibition by the isoflavones genistein and biochanin A. Carcinogenesis 17:1861-1869.
  • Potter, SM. 1998. Soy protein and cardiovascular disease: The impact of bioactive components in soy. Nutr Rev 56:231-235.
  • Potter SM, Bakhit RM, Essex-Sorlie DL, Weigartner KE, Chapman KM, Nelson RA, Prabhudesai M, Savage WD, Nelson AI, Winter LW and Erdman JW. 1993. Depression of plasma cholesterol in men by consumption of baked products containing soy protein. Am J Clin Nutr 58:501-506.
  • Potter, SM, Baum, JA, Teng, H, Stillman, RJ, Shay, NF, and Erdman, JW Jr. 1998. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 68 (6 Suppl):1375S-1379S.
  • Rauth S, Kichina J, Green A. 1997. Inhibition of growth and induction of differentiation of metastatic melanoma cells in vitro by genistein: chemosensitivity is regulated by cellular p53. Br J Cancer 75:1559-1566.
  • Ross, PD. 1996. Osteoporosis. Frequency, consequences and risk factors. Arch Int Med 156:1399-1411.
  • Setchell KDR. 1998. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr 68(suppl):1333S-1346S.
  • Shao, ZM, Wu, J, Shen, ZZ, and Barsky, SH. 1998. Genistein exerts multiple suppressive effects on human breast carcinoma cells. Cancer Res 58:4851-4857.
  • Shaw CR. 1997. The perimenopausal hot flash: epidemiology, physiology, and treatment. Nurse Pract 22(3):55-56,61-66.
  • Shutt DA, Cox RI. 1972. Steroid and phytoestrogen binding to sheep uterine receptors in vitro. J Endocrinol 52:299-310.
  • So FV, Guthrie N, Chambers AF, Moussa M, Carroll KK. 1996. Inhibition of human breast cell proliferation by flavonoids and citrus juice. Nutr Cancer 26:167-181.
  • Stampfer MJ, Colditz GA, Willett WC, et al. 1991. Postmenopausal estrogen therapy and cardiovascular disease. Ten year follow-up from the nurses' health study. N Engl J Med 325:756-762.
  • Steinberg D. 1997. Oxidative modification of low density lipoprotein and atherosclerosis. Circulation 95:1062-1071.
  • Tham, DM, Gardner, CD, and Haskell, WL. 1998. Clinical Review 97. Potential health benefits of dietary phytoestrogens: A review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab 83:2223-2235.
  • Thiagarajan, DG, Bennink, MR, Bourquin, LD, and Kavas, FA. 1998. Prevention of precancerous colonic lesions in rats by soy flakes, soy flour, genistein, and calcium. Am J Clin Nutr 68 (6 Suppl):1394S-1399S.
  • Teixeira S, Potter SM, Weigel R, Hannum S, Erdman JW and Hasler CM. 1998. Dose-dependent effects of soy protein in hypercholesterolemic men. FASEB J 12:A237.
  • Traganos F, Ardelt B, Halko N, Bruno S, Darzynkiewicz Z. 1992. Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells. Cancer Res 52:6200-6208.
  • Tsuda M, Kitazaki T, Ito T, Fujita T. 1986. The effect of ipriflavone (TC-80) on bone resorption in tissue culture. J Bone Miner Res 1:207-211.
  • Wardell, DW, and Engebretson, JC. 1995. Women’s anticipations of hormone replacement therapy. Maturitas 22:177-183.
  • Wei H, Bowen R, Cai Q, Barnes S, Wang Y. 1995. Antioxidant and antipromotional effects of the soybean isoflavone genistein. Proc Soc Exp Biol Med 208:124-130.
  • Wong WW, Hachey DL, Clarke LL and Zhang S. 1995. Chlesterol synthesis and absorption by 2H2O and 18O-cholesterol and hypercholesterolemic effect of soy protein. J Nutr 125:612S-618S.
  • Yanagihara K, Ito A, Toge T, Numoto M. 1993. Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract. Cancer Res 53:5815-5821.
  • Zhou, JR, Mukherjee, P, Gugger, ET, Tanaka, T, Blackburn, GL, and Clinton, SK. 1998. Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis. Cancer Res 58:5231-5238.
  • Zava DT, Duwe G. 1997. Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro. Nutr Cancer 27:31-40.

1-833-888-3674 | Terms & Conditions | Privacy Statement | About Us | Contact Us
ssl ©  Copyright 2008-2024 - iWinDirect - Direct NutriSciences we accept visa, mastercard, american express and paypal